ReviewHealth economics review2026
Economic and health-related quality of life impacts of posttraumatic stress disorder: a systematic review.
Review in Health economics review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-traumatic stress disorder (PTSD) is a severe psychiatric condition associated with long-term mental health impairment, high healthcare utilization, and substantial societal costs. Despite growing recognition of its burden, few reviews integrate economic and health-related quality of life (HRQoL) impacts. This systematic review synthesizes global evidence on the economic and HRQoL consequences of PTSD to inform policy decision-making.
methodsA systematic search of six databases (Web of Science, EMBASE, MEDLINE, PsycINFO, PubMed, and EconLit) was conducted in April 2024 and updated in April 2025. Studies reporting real-world costs or HRQoL outcomes in PTSD populations were included. Quality was assessed using the Joanna Briggs Institute critical appraisal tools. Data were synthesized narratively due to heterogeneity in study design, populations, and outcome measures.
resultsTwenty studies met inclusion criteria, spanning 2000-2024 and representing diverse settings including the US, Europe, South Korea, and Australia. However, most were from high-income countries, with limited representation from low- and middle-income countries (LMICs). PTSD was associated with high direct healthcare costs (e.g., $66.0 billion in US civilians) and substantial indirect costs from lost productivity, disability, caregiving, and premature mortality. Veterans and conflict-affected populations bore particularly high economic burdens. HRQoL was markedly reduced across all populations studied, with EQ-5D, AQoL, and MANSA scores indicating significant functional and psychosocial impairment. Co-occurring conditions (e.g., depression, anxiety), trauma severity, and sleep disturbances were key drivers of reduced HRQoL.
conclusionsPTSD imposes a substantial economic and quality of life burden globally. Findings provide evidence supporting the need for comprehensive treatment approaches, long-term support systems, and policies that address both economic and psychosocial outcomes in PTSD care.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.